天域生物公告，2025年8月，公司销售生猪2.60万头，销售收入2984.23万元，环比变动分别为50.83%、 41.89%，同比变动分别为2.04%、-53.32%。1-8月，公司累计销售生猪24.74万头，同比上升17.77%；累 计销售收入36240.60万元，同比下降0.05%。8月末，公司生猪存栏18.10万头，同比上升22.29%，环比 上升10.49%。 (本文来自第一财经) ...

证券代码：603717 证券简称：天域生物 公告编号：2025-077 天域生物科技股份有限公司 2025 年 8 月养殖业务主要经营数据公告 月度主要经营数据汇总如下： 注：因四舍五入，以上数据可能存在尾差。 二、特别提示 1、上述经营数据均未经审计，与定期报告披露的数据之间可能存在差异， 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）现将 2025 年 8 月养殖业务 主要经营数据公告如下： 一、2025 年 8 月养殖行业主要经营数据 2025 年 8 月，公司销售生猪 2.60 万头，销售收入 2,984.23 万元，环比变动分 别为 50.83%、41.89%，同比变动分别为 2.04%、-53.32%。 2025 年 1-8 月，公司累计销售生猪 24.74 万头，同比上升 17.77%；累计销售 收入 36,240.60 万元，同比下降 0.05%。 2025 年 8 月末，公司生猪存栏 18.10 万头，同比上升 22.29%，环比上升 10.49%。 | | 月份 ...

人民财讯9月5日电，天域生物（603717）9月5日晚间公告，2025年8月，公司销售生猪2.6万头，销售收 入2984.23万元，环比变动分别为50.83%、41.89%，同比变动分别为2.04%、-53.32%。 2025年1—8月，公司累计销售生猪24.74万头，同比上升17.77%；累计销售收入3.62亿元，同比下降 0.05%。 ...

天域生物（603717）(603717.SH)发布公告，2025年8月，公司销售生猪2.60万头，销售收入2984.23万 元，环比变动分别为50.83%、41.89%，同比变动分别为2.04%、-53.32%。2025年1-8月，公司累计销售 生猪24.74万头，同比上升17.77%;累计销售收入3.62亿元，同比下降0.05%。2025年8月末，公司生猪存 栏18.10万头，同比上升22.29%，环比上升10.49%。 ...

Core Insights - Tianyu Biological (603717.SH) reported sales of 26,000 pigs in August 2025, generating revenue of 29.84 million yuan, with a month-on-month increase of 50.83% in sales and 41.89% in revenue, but a year-on-year decrease of 2.04% in sales and 53.32% in revenue [1] Sales Performance - Cumulative sales of pigs from January to August 2025 reached 247,400 heads, representing a year-on-year increase of 17.77% [1] - Cumulative sales revenue for the same period was 362 million yuan, showing a slight year-on-year decline of 0.05% [1] Inventory Status - As of the end of August 2025, the company's pig inventory stood at 181,000 heads, reflecting a year-on-year increase of 22.29% and a month-on-month increase of 10.49% [1]

Core Viewpoint - Tianyu Biotechnology Co., Ltd. is convening its third extraordinary general meeting of shareholders in 2025 to discuss various proposals, including a plan for issuing A-shares to specific investors, aimed at enhancing the company's capital structure and supporting its operational needs [1][2][10]. Group 1: Meeting Proposals - Proposal 1: The company meets the conditions for issuing A-shares to specific investors, having conducted a thorough self-assessment against regulatory requirements [10]. - Proposal 2: The plan for the 2025 issuance of A-shares to specific investors is outlined, with the issuance to be conducted at an appropriate time after regulatory approvals [11][12]. - Proposal 3: A detailed analysis report on the 2025 A-share issuance plan has been prepared and is available for review [19][20]. - Proposal 4: A feasibility analysis report on the use of funds raised from the A-share issuance has been compiled [21]. - Proposal 5: A special report on the use of previously raised funds has been prepared and audited [22]. - Proposal 6: The company will sign a conditional share subscription agreement with a related party, which is compliant with regulatory standards [23]. - Proposal 7: The impact of the A-share issuance on immediate returns and measures to mitigate any dilution of returns have been analyzed [25]. - Proposal 8: A three-year shareholder return plan (2025-2027) has been developed to enhance transparency in profit distribution [26]. - Proposal 9: The board seeks authorization to manage all matters related to the A-share issuance, including adjustments based on market conditions and regulatory requirements [30][32].

2025 年第三次临时股东大会会议资料 天域生物科技股份有限公司 2025 年第三次临时股东大会会议资料 二 O 二五年九月十一日 2025 年第三次临时股东大会会议资料 天域生物科技股份有限公司 2025 年第三次临时股东大会会议资料目录 一、本次会议设立股东大会会务组，具体负责会议期间的组织及 相关会务工作。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法 权益，务请出席大会的股东或股东代理人（以下统称"股东"）及相关 人员准时到达会场签到确认参会资格。股东参会登记当天没有通过电 话、邮件或传真方式登记的，不在签到表上登记签到的，或会议正式 开始后没有统计在会议公布股权数之内的股东或股东代理人，不参加 表决和发言。 三、请参会人员自觉遵守会场秩序，进入会场后，请关闭手机或 调至振动状态。 四、股东在会议召开期间准备发言的，请在会议开始前到大会会 务组登记并填写"股东大会发言登记表"。股东临时要求发言或就相关 问题提出质询的，应当先向大会会务组申请，经大会主持人许可后方 可。 | 年第三次临时股东大会会议须知 2 | 2025 | | --- | --- | | 年第三次临时股东大会会议议程 4 ...

Core Insights - Tianyu Bio (603717.SH) reported a total operating revenue of 412 million yuan for the first half of 2025, with a net profit attributable to shareholders of 10.82 million yuan, marking an increase of 4.59 million yuan compared to the same period last year, representing a year-on-year growth of 73.68% [1] - The company achieved a net cash inflow from operating activities of 89.83 million yuan, an increase of 31.90 million yuan from the same period last year, reflecting a year-on-year growth of 55.07% [1] Financial Performance - The latest debt-to-asset ratio stands at 75.62%, a decrease of 0.29 percentage points from the previous quarter [3] - The gross profit margin is reported at 14.64%, ranking 10th among disclosed peers [3] - Return on equity (ROE) is at 2.04%, an increase of 1.09 percentage points year-on-year, ranking 11th among disclosed peers [3] - The diluted earnings per share (EPS) is 0.04 yuan, an increase of 0.02 yuan compared to the same period last year, reflecting a year-on-year growth of 73.49% [3] - The total asset turnover ratio is 0.13 times, remaining stable compared to the same period last year, with a year-on-year increase of 2.57% [3] - The inventory turnover ratio is reported at 1.66 times [3] Shareholder Structure - The number of shareholders is 20,200, with the top ten shareholders holding a total of 115 million shares, accounting for 39.53% of the total share capital [3] - The top shareholders and their respective holdings are as follows: - T: 12.84% - Shi Dongwei: 11.15% - Shenzhen Zeyuan Private Securities Fund Management Co., Ltd.: 7.58% - Mao Shiqi: 2.67% - Ren Chao: 0.98% - Li Jixiang: 0.97% - Shanghai Luran Investment Management Co., Ltd.: 0.90% - Cha Qizuo: 0.89% - Ding Tai Sifang (Shenzhen) Private Fund Management Co., Ltd.: 0.80% - Barclays Bank PLC: 0.76% [3]

Core Viewpoint - Tianyu Biological (603717) has experienced a decline in stock price and market capitalization, with significant changes in shareholder structure and financial performance reported in recent disclosures [1][2][3]. Group 1: Stock Performance - As of August 29, 2025, Tianyu Biological's stock closed at 8.26 yuan, down 3.73% from the previous week [1]. - The stock reached a peak of 9.25 yuan on August 25, 2025, and a low of 8.09 yuan on August 28, 2025 [1]. - The company's current total market capitalization is 2.397 billion yuan, ranking 23rd in the aquaculture sector and 4866th in the A-share market [1]. Group 2: Shareholder Changes - As of June 30, 2025, the number of shareholders decreased to 20,200, a reduction of 413 shareholders or 2.0% from March 31, 2025 [1]. - The average number of shares held per shareholder increased from 14,100 to 14,400, with an average holding value of 104,100 yuan [1]. - The actual controller of the company has changed to Luo Weiguo following the termination of the concerted action relationship with Shi Dongwei, who relinquished voting rights for 32,338,800 shares [3]. Group 3: Financial Performance - The company's mid-year report for 2025 shows a main revenue of 412 million yuan, a year-on-year decrease of 2.62% [2]. - The net profit attributable to shareholders increased to 10.818 million yuan, a year-on-year rise of 73.68% [2]. - The company reported a negative non-recurring net profit of 19.3017 million yuan, a significant decline of 528.8% year-on-year [2]. Group 4: Corporate Announcements - On August 25, 2025, the company approved a plan to issue A-shares to specific investors, with a maximum of 71,028,297 shares at a price of 6.55 yuan per share, aiming to raise up to 465.2353 million yuan for working capital and debt repayment [3]. - The company has committed to a shareholder return plan for 2025-2027, promising annual cash dividends of at least 10% of distributable profits, and at least 80% when there are no major expenditures [3]. - The company has not faced regulatory penalties in the past five years and has rectified previous issues related to information disclosure and impairment provisions [3].

Core Viewpoint - Tianyu Biological (603717) reported a mixed financial performance for the first half of 2025, with a decline in total revenue but a significant increase in net profit compared to the previous year [1] Financial Performance Summary - Total revenue for the first half of 2025 was 412 million yuan, a decrease of 2.62% year-on-year [1] - Net profit attributable to shareholders reached 10.82 million yuan, an increase of 73.68% year-on-year [1] - In Q2 2025, total revenue was 187 million yuan, down 11.87% year-on-year, while net profit was -2.95 million yuan, a decline of 5.38% year-on-year [1] - The gross margin was 14.63%, a decrease of 1.97% year-on-year, while the net margin improved to 7.73%, an increase of 138.86% year-on-year [1] - Total operating expenses (selling, administrative, and financial) amounted to 58.23 million yuan, accounting for 14.12% of revenue, an increase of 19.65% year-on-year [1] Balance Sheet Highlights - Cash and cash equivalents decreased to 158 million yuan, down 12.17% year-on-year [1] - Accounts receivable stood at 340 million yuan, a decrease of 4.45% year-on-year, representing 42.36% of total revenue [1] - Interest-bearing liabilities decreased to 1.248 billion yuan, down 8.67% year-on-year [1] - Book value per share was 1.83 yuan, a decrease of 18.84% year-on-year [1] - Earnings per share increased to 0.04 yuan, up 73.49% year-on-year [1] - Operating cash flow per share improved to 0.31 yuan, an increase of 55.07% year-on-year [1] Business Evaluation - The company's historical return on invested capital (ROIC) has been generally low, with a median of 6.66% since its listing, and a particularly poor ROIC of -24.52% in 2023 [1] - The company has reported losses in five out of its seven annual reports since going public, indicating a challenging financial history [1]